GlassScriptPhysician profile
Raymond Baule
NPI 1962619023
$8,706.16
in general payments reported to CMS, 2019-2025
30 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.81 · 2020: $952 · 2021: $1,374 · 2022: $2,068 · 2023: $1,729 · 2024: $1,086 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,636 · Consulting Fee: $421 · Education: $219 · Entertainment: $24.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,635.99 |
| Consulting Fee | $421.25 |
| Education | $218.86 |
| Entertainment | $24.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $2,232.90 | 2021-2023 | Simplify Cervical Artificial Disc, Ilif, Tlx |
| Medtronic, INC. | $989.96 | 2021-2025 | Osteocool Rf Ablation System, Catalyft Pl Expandable Interbody System, Kyphon Express II Kyphopak Tray |
| Globus Medical, INC. | $829.63 | 2024-2025 | Hedron, Independence, Coalition Mis / Mis Ti |
| Boston Scientific Corporation | $453.48 | 2022-2025 | Varithena Administration Pack, Intracept |
| Medtronic USA, INC. | $431.91 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $421.25 | 2024 | Combogesic IV |
| Abbott Laboratories | $418.49 | 2020-2024 | Proclaim |
| Stryker Corporation | $364.93 | 2021-2024 | Omnicurve |
| Zimvie INC. | $269.15 | 2023 | |
| Djo, LLC | $263.54 | 2021-2024 | Cmf |
| 4web, INC. | $220.82 | 2020-2021 | |
| Depuy Synthes Sales INC. | $216.85 | 2020-2025 | Fibergraft Bg Morsels |
| Cerapedics INC. | $215.00 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Orthofix Medical, INC. | $189.97 | 2023-2025 | Spinal-Stim, Spinal-Stim |
| Si-Bone, INC. | $174.29 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $159.74 | 2022 | |
| Highridge Medical LLC | $148.06 | 2024 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Relievant Medsystems, INC. | $122.62 | 2022 | |
| Royal Biologics, INC. | $105.77 | 2021 | |
| Abbvie INC. | $86.85 | 2022-2024 | Teflaro, Avycaz, Dalvance |
| Impulse Dynamics (USA) INC. | $76.22 | 2023 | Optimizer |
| Merck Sharp & Dohme LLC | $72.68 | 2022-2025 | Bridion |
| Microtransponder, INC. | $45.31 | 2025 | |
| Avanos Medical | $37.70 | 2025 | Standard Rf Disposables |
| Cumberland Pharmaceuticals, INC. | $34.83 | 2023-2025 | Caldolor |
| Centinel Spine, LLC | $32.50 | 2023 | Prodisc C Vivo |
| Providence Medical Technology, INC. | $27.62 | 2024 | |
| Spinal Elements, INC. | $24.68 | 2024 | |
| Shionogi INC | $22.72 | 2025 | Fetroja |
| Spineology INC. | $16.69 | 2025 | Optimesh Expandable Interbody Fusion System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Baule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.